It has been reported that vaccination with CA-IX-derived peptides is an effective immunotherapy for renal cell carcinoma patients (25), and that the addition of bevacizumab, a humanized anti-VEGF monoclonal antibody, to conventional therapy for patients with cervical cancer improves survival rates (26). Here, CA9 is linked to hereditary clear cell renal cell carcinoma.